Company history

Company history and investors

Cinclus Pharma AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Its drug candidate linaprazan glurate has successfully completed a phase I clinical study.


The company was founded in 2014 by Kjell Andersson, Peter Unge, Lennart Hansson, Mikael Dahlström, Urban Paulsson and Marek Poszepczynski.


The members of Cinclus Pharma’s management team were key members of the project teams that developed AstraZeneca’s blockbuster drugs Losec and Nexium.

Cinclus is latin for the European dipper.  

Photo: Thomas Lundquist


During 2001-2005 AstraZeneca performed 23 phase I and two phase II clinical studies of its P-CAB drug candidate linaprazan in over 2,500 patients. The studies showed that linaprazan was well tolerated, with a fast onset of action and full effect already at first dose. However, linaprazan was quickly eliminated from the body and the duration of acid blocking was too short. Consequently, AstraZeneca decided to shut down the linaprazan project.


One of the founders of Cinclus Pharma, Kjell Andersson, was at that time preclinical project leader at AstraZeneca. Together with his colleague Mikael Dahlström, he acquired the rights to the prodrugs of linaprazan. One such prodrug is linaprazan glurate. The compound provides a longer half-life in the body than linaprazan itself, provides total control of gastric acid production and is tailored for GERD patients with severe esophagitis.


Cinclus Pharma has performed its first clinical study of linaprazan glurate with positive results and is now to launch a comprehensive and de-risked clinical development program to progress its drug candidate towards registration. The successful launch by Takeda of the first P-CAB drug, Takecab, in Japan has further proven the high unmet medical need highlighting the potential for linaprazan glurate.

Shareholder base

The shareholder base of Cinclus Pharma includes investors like
the Fourth Swedish National Pension Fund (AP4), Bengt Julander via Linc AB, Jonas Sjögren and Recipharm Venture Fund. Management holds 19% of the shares